The Experts below are selected from a list of 39 Experts worldwide ranked by ideXlab platform
Tony R Reid - One of the best experts on this subject based on the ideXlab platform.
-
5 10 Methylenetetrahydrofolic Acid with 5 fluorouracil as first line treatment in metastatic colorectal cancer phase ii study results
Journal of Clinical Oncology, 2006Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milinic, L Muzikravic, J RobbinsAbstract:3599 Background: 5-Fluorouracil (FU) plus Leucovorin (LV) has historically been the standard first line treatment of colorectal cancer. Although LV modestly enhances FU activity, it can increase sy...
-
a simon 2 stage study of 5 10 Methylenetetrahydrofolic Acid co with 5 fluorouracil fu as first line treatment in metastatic colorectal cancer mcrc
Journal of Clinical Oncology, 2005Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milini, L MuzikravicAbstract:3692 Background: We are conducting an open label, Simon 2 stage study to assess the safety and efficacy of CO+FU for first line treatment in mCRC. Unlike leucovorin (LV), CO directly modulates FU i...
C P Spears - One of the best experts on this subject based on the ideXlab platform.
-
5 10 Methylenetetrahydrofolic Acid with 5 fluorouracil as first line treatment in metastatic colorectal cancer phase ii study results
Journal of Clinical Oncology, 2006Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milinic, L Muzikravic, J RobbinsAbstract:3599 Background: 5-Fluorouracil (FU) plus Leucovorin (LV) has historically been the standard first line treatment of colorectal cancer. Although LV modestly enhances FU activity, it can increase sy...
-
a simon 2 stage study of 5 10 Methylenetetrahydrofolic Acid co with 5 fluorouracil fu as first line treatment in metastatic colorectal cancer mcrc
Journal of Clinical Oncology, 2005Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milini, L MuzikravicAbstract:3692 Background: We are conducting an open label, Simon 2 stage study to assess the safety and efficacy of CO+FU for first line treatment in mCRC. Unlike leucovorin (LV), CO directly modulates FU i...
-
chemical stability and human plasma pharmacokinetics of reduced folates
Cancer Investigation, 1998Co-Authors: Elisabeth Odin, Goran Carlsson, Roland Frosing, Bengt Gustavsson, C P Spears, P A LarssonAbstract:The in vitro stability and plasma pharmacokinetics of 5,10-Methylenetetrahydrofolic Acid (CH2FH4), tetrahydrofolic Acid (FH4), 5-methyltetrahydrofolic Acid (CH, FH4), and 5-formyltetrahydrofolic Acid (5-CHOFH4) were studied in view of their potential usefulness in cancer chemotherapy. Analysis of reduced folates was done on a high-performance liquid chromatography (HPLC) system. The high sensitivity of FH4 and CH2FH4 to oxidation can be circumvented by use of high concentrations of the folates, addition of ascorbate, and by thorough exclusion of atmospheric O2. Intravenous injection of 200 mg FH4 or CH2FH4 resulted in average peak concentrations of 69.2 ± 3.2 nmol/ml and 46.3 ± 2.6 nmol/ml, respectively. The plasma concentration curves support the concept that these highly oxygen-sensitive reduced folates can be reliably administered as pharmaceuticals to cancer patients through the use of a suitable air-occlusive system for their preparation and administration.
L Muzikravic - One of the best experts on this subject based on the ideXlab platform.
-
5 10 Methylenetetrahydrofolic Acid with 5 fluorouracil as first line treatment in metastatic colorectal cancer phase ii study results
Journal of Clinical Oncology, 2006Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milinic, L Muzikravic, J RobbinsAbstract:3599 Background: 5-Fluorouracil (FU) plus Leucovorin (LV) has historically been the standard first line treatment of colorectal cancer. Although LV modestly enhances FU activity, it can increase sy...
-
a simon 2 stage study of 5 10 Methylenetetrahydrofolic Acid co with 5 fluorouracil fu as first line treatment in metastatic colorectal cancer mcrc
Journal of Clinical Oncology, 2005Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milini, L MuzikravicAbstract:3692 Background: We are conducting an open label, Simon 2 stage study to assess the safety and efficacy of CO+FU for first line treatment in mCRC. Unlike leucovorin (LV), CO directly modulates FU i...
J Robbins - One of the best experts on this subject based on the ideXlab platform.
-
5 10 Methylenetetrahydrofolic Acid with 5 fluorouracil as first line treatment in metastatic colorectal cancer phase ii study results
Journal of Clinical Oncology, 2006Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milinic, L Muzikravic, J RobbinsAbstract:3599 Background: 5-Fluorouracil (FU) plus Leucovorin (LV) has historically been the standard first line treatment of colorectal cancer. Although LV modestly enhances FU activity, it can increase sy...
S Jelic - One of the best experts on this subject based on the ideXlab platform.
-
5 10 Methylenetetrahydrofolic Acid with 5 fluorouracil as first line treatment in metastatic colorectal cancer phase ii study results
Journal of Clinical Oncology, 2006Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milinic, L Muzikravic, J RobbinsAbstract:3599 Background: 5-Fluorouracil (FU) plus Leucovorin (LV) has historically been the standard first line treatment of colorectal cancer. Although LV modestly enhances FU activity, it can increase sy...
-
a simon 2 stage study of 5 10 Methylenetetrahydrofolic Acid co with 5 fluorouracil fu as first line treatment in metastatic colorectal cancer mcrc
Journal of Clinical Oncology, 2005Co-Authors: Tony R Reid, C P Spears, R Quadro, M Subramanian, L Pawl, G Jankovic, S Jelic, N Milini, L MuzikravicAbstract:3692 Background: We are conducting an open label, Simon 2 stage study to assess the safety and efficacy of CO+FU for first line treatment in mCRC. Unlike leucovorin (LV), CO directly modulates FU i...